@vikas_sinha - Firstly, congratulations on achieving 33% CAGR over almost 7 years, that quite an achievement. Do you mind sharing why you think Beta Drugs is a mistake? Would like to understand your anti-thesis on it. Per me, it has the following things going for it:
Strong R&D setup in place
Indian Oncology Drug market is on the rise
It is a net debt free company
High ROE and ROCE business and steady operating margins of 18-19%
It’s expecting 290cr+ revenue for FY24
And I also believe you have been tracking Arman Financials for a while now, what according to you is the hold up with it? Is it the recent increase in NPAs or is there more to it? It’s been consolidating for a year now, which I think is good. But when it comes to triggers which will make it regain its upward trajectory again, what do think those are?
Thanks in advance !
Subscribe To Our Free Newsletter |